Vivo Ventures: Our Portfolio

Our Portfolio

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates.

www.acurapharm.com

AMAG Pharmaceuticals (NASDAQ: AMAG) is developing iron nanoparticle-based therapeutics. The company’s lead product, ferumoxytol, is in Phase III trials for anemia associated with chronic kidney disease.

www.amagpharma.com

Abraxis Bioscience, Inc. (NASDAQ: ABBI) is a strategically integrated pharmaceutical company that manufactures, markets and develops injectable products, with a focus on oncology and anti-infectives.

www.abraxisbio.com

APT Pharmaceuticals is a clinical-stage company developing products to treat respiratory diseases.

www.aptbio.com

Aspreva Pharmaceuticals (NASDAQ: ASPV) is a pharmaceutical company which identifies, develops and commercializes new applications for existing medicines. Acquired by Galenica.

Avanir Pharmaceuticals (NASDAQ: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. The company's lead product, Zenvia, is currently in Phase III clinical trials for the treatment of pseudobulbar affect.

www.avanir.com

Biodel, Inc. is a biopharmaceutical drug delivery company with an insulin-based product, Viaject, in late-stage clinical trials for the treatment of diabetes.

www.biodel.com

BioForm Medical, Inc. is developing and commercializing Radiesse and Coaptite, proprietary gels containing calcium hydroxylapatite, for cosmetic applications, stress urinary incontinence (SUI), vocal cord insufficiency and paralysis (VFI), and other disorders. Acquired by Merz.

www.bioform.com

Capnia is developing novel treatments for migraine headache and allergic rhinitis, both multi-billion dollar markets.

www.capnia.com

Carbylan Biosurgery is a medical device company developing chemically engineered hyaluronic acid polymers as therapeutics for the treatment of osteoarthritis and chronic sinusitis.

www.carbylan.com

Chelsea Therapeutics (NASDAQ: CHTP) acquires, develops and commercializes innovative products for the treatment of important unmet medical needs such as rheumatoid arthritis, psoriasis, and other inflammatory conditions.

www.chelseatherapeutics.com

CoTherix (NASDAQ: CTRX) is marketing Ventavis® (iloprost aerosol) for the treatment of primary pulmonary hypertension, an orphan indication, for the U.S. market. Acquired by Actelion.

Dynavax Technologies (NASDAQ: DVAX) is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

www.dynavax.com

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C and Hepatitis D, and a wide array of other viruses.

www.eigerbio.com

Essentialis is developing a novel therapy for the treatment of dyslipidemia.

www.essentialistherapeutics.com

Hamilton Pharmaceuticals, Inc. (HPI) is developing novel treatments for central nervous system disease. Acquired by Neuren.

Intekrin is a clinical stage biopharmaceutical company focused on the development of products for diabetes, metabolism, and obesity.

www.intekrin.com

InterMune (NASDAQ: ITMN) is a biopharmaceutical company focused on the applied research, development and marketing of life-saving therapies for pulmonary and hepatic diseases.

www.intermune.com

KangHui Medical is a leading Chinese orthopedic device manufacturer with products in trauma, spine, and joint implants.

www.kanghui-international.com

Lee’s Pharmaceutical Holdings Limited (8221: HKEX) is a research and market-driven company developing innovative pharmaceuticals for the greater China market.

www.leespharm.com

MacroGenics, Inc. is developing antibodies and vaccines in the areas of oncology, inflammation, allergy, and infectious diseases.

www.macrogenics.com

NeoMend, Inc. is a privately held, clinical stage medical device company that has developed a proprietary platform technology which seals and facilitates healing of soft tissue wounds caused by trauma or surgical procedures.

www.neomendinc.com

NextWave Pharmaceuticals is focused on developing innovative products for the pediatric pharmaceutical market. The company is developing and commercializing products that address many of the compliance, convenience, dosing and safety issues children and their parents face today.

www.nextwavepharma.com

Palatin (AMEX:PTN) is developing melanocortin-based therapeutics. The company’s lead product, bremelanotide, is in Phase II clinical trials for female and male sexual dysfunction.

www.palatin.com

Pavad Medical is developing implantable sleep apnea therapies.

www.pavad.com

Prestwick Pharmaceuticals is a specialty pharmaceutical company engaged in the development and marketing of drugs for diseases of the CNS. Acquired by Biovail.

Revance Therapeutics is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology.

www.revance.com

Sagent Pharmaceuticals is an international pharmaceutical company bringing finished pharmaceutical products to the U.S. market.

www.sagentpharma.com

Synapse BioMedical is a medical device company developing neurostimulation products for spinal cord injury and ALS patients.

www.synapsebiomedical.com

Transcept Pharmaceuticals is developing products that utilize the company's proprietary drug delivery system.

www.transcept-pharma.com

TRIA Beauty, formerly known as SpectraGenics, is a leader in light-based therapeutic beauty systems that incorporate clinically-proven aesthetic technologies for at-home personal care regimens.

www.triabeauty.com

Vicept Therapeutics is developing dermatology therapeutic products.

www.vicepttx.com

Yaupon Therapeutics is a privately held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The company’s lead program, Clearazide, is completing Phase III trials for the treatment of cutaneous T-cell lymphoma (CTCL).

www.yaupontherapeutics.com